11.8 C
New York
Thursday, April 25, 2024

Comment by jmd__

View Single Comment

  1. jmd__

    Phil, looking at ILMN as a long term hold due to what I think is a moat in technology that will be increasingly incorporated with increasing availability to primary testing: genetics. Docs (I'm one) can now order screening tests as to patients susceptibility to various diseases and will soon order tests to determine what meds to prescribe. Any way, earnings Monday; what do you think? Also curious as to what you or pharm or others in the community think of the moat.



Stay Connected

157,326FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles